KORU Medical Systems (KRMD) Projected to Post Earnings on Wednesday

KORU Medical Systems (NASDAQ:KRMD) will likely be issuing its quarterly earnings data after the market closes on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

KORU Medical Systems Trading Down 3.3 %

NASDAQ KRMD opened at $3.19 on Wednesday. KORU Medical Systems has a 12 month low of $2.04 and a 12 month high of $5.05. The company has a current ratio of 2.99, a quick ratio of 2.37 and a debt-to-equity ratio of 0.01. The business’s 50-day moving average price is $4.08 and its two-hundred day moving average price is $3.36. The firm has a market capitalization of $146.22 million, a PE ratio of -12.76 and a beta of 0.45.

Wall Street Analysts Forecast Growth

KRMD has been the topic of several recent research reports. Piper Sandler reiterated a “neutral” rating and issued a $4.50 price target on shares of KORU Medical Systems in a report on Friday, February 14th. Craig Hallum raised their target price on KORU Medical Systems from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. Lake Street Capital raised their price target on KORU Medical Systems from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, January 14th. Finally, Canaccord Genuity Group lifted their price objective on KORU Medical Systems from $3.00 to $4.00 and gave the company a “buy” rating in a research note on Thursday, November 14th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, KORU Medical Systems presently has a consensus rating of “Buy” and a consensus price target of $4.70.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.